Reactive Oxygen Species and Cardiac Preconditioning: Many Questions Remain David F. StoweMatthias L. Riess Editorial Introduction Pages: 87 - 90
Do Pharmacological Differences Among Beta-Blockers Affect Their Clinical Efficacy in Heart Failure? Andrea Di LenardaGastone SabbadiniGianfranco Sinagra Editorial Introduction Pages: 91 - 93
ICD's in Congestive Heart Failure—Is There Bang for the Beat? Thomas D. SzucsLukas Kappenberger Editorial Introduction Pages: 95 - 98
Nitric Oxide Synthase (NOS) Does Not Contribute to Simulated Ischaemic Preconditioning in an Isolated Rat Cardiomyocyte Model Hans StrijdomSonia GenadeAmanda Lochner OriginalPaper Pages: 99 - 112
Myocardial Protection from Either Ischaemic Preconditioning or Nicorandil Is Not Blocked by Gliclazide Helen L. MaddockSylvia M. SiedleckaDerek M. Yellon OriginalPaper Pages: 113 - 119
Acetaminophen and Experimental Acute Myocardial Infarction Sharon L. HaleRobert A. Kloner OriginalPaper Pages: 121 - 125
Omapatrilat Limits Infarct Size and Lowers the Threshold for Induction of Myocardial Preconditioning Through a Bradykinin Receptor-Mediated Mechanism Z. EbrahimG.F. BaxterD.M. Yellon OriginalPaper Pages: 127 - 134
Different Effects of Exercise on Plasma Concentrations of Nebivolol, Bisoprolol and Carvedilol Kurt StoschitzkyGergana StoschitzkyWolfgang Lindner OriginalPaper Pages: 135 - 138
A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET) John G.F. ClelandKevin GoodeChristian Torp-Pedersen OriginalPaper Pages: 139 - 152
Increasing Awareness and Perception of Heart Failure in Europe and Improving Care—Rationale and Design of the SHAPE Study Willem RemmeAlessandro BoccanelliFaiez Zannad OriginalPaper Pages: 153 - 159
Cost-Effectiveness of Primary Implanted Cardioverter Defibrillator for Sudden Death Prevention in Congestive Heart Failure Lei ChenJoel W. Hay OriginalPaper Pages: 161 - 170